Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03417505 · ClinicalTrials.gov registry record · NA
Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye
A NA study, sponsored by Tangible Science.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT03417505: Completed NA study, sponsored by Tangible Science.
NCT03417505 is a NA study that has completed, run by Tangible Science. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03417505, a NA study, has completed, sponsored by Tangible Science.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
Tangible Hydra-PEG is a novel coating technology designed to improve lens wettability, deposit resistance, and tear film breakup time. This is a randomized double masked cross-over study to examine contact lens discomfort and dry eye symptoms with Tangible Hydra-PEG treated scleral lens wear compared to untreated scleral lens wear in the dry eye patient population.
Primary Outcome
Tear breakup time of the ocular surface after wearing lenses
Interventions
- DEVICE Scleral lenses treated with Tangible Hydra-PEG
- DEVICE Untreated scleral lenses
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-01-30 |
| Est. Completion | 2019-01-04 |
| Phase | NA |
What the finished NCT03417505 record still lists
NCT03417505 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Scleral lenses treated with Tangible Hydra-PEG is the first listed.
NCT03417505 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03417505 about?
NCT03417505 is a clinical study titled "Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye". Tangible Hydra-PEG is a novel coating technology designed to improve lens wettability, deposit resistance, and tear film breakup time. This is a randomized double masked cross-over study to examine contact lens discomfort and dry eye symptoms with Tangible Hydra-PEG treated scleral lens wear compare...
What is the current status of trial NCT03417505?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2018-01-30. Estimated completion is 2019-01-04.
What interventions are being tested in trial NCT03417505?
The interventions under investigation include: Scleral lenses treated with Tangible Hydra-PEG (DEVICE), Untreated scleral lenses (DEVICE).
Who is sponsoring clinical trial NCT03417505?
This trial is sponsored by Tangible Science, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03417505's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI